Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02894307Unknown

Rivaroxaban in Mechanical Valves: RMV Study

Role: lead

NCT02797145Phase 2Unknown

Intensive Versus Conventional Digoxin Use in Patients With Heart Failure

Role: lead

NCT01868243Phase 2Terminated

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Role: lead

NCT02384798Not ApplicableCompleted

Ventilatory Support Associated With Exercise in Heart Failure

Role: collaborator

NCT01936350Phase 2Completed

Sildenafil Impact on Ventricular Function in Patients With Heart Failure

Role: lead

All 5 trials loaded